31503-28-3

Upstream product

• 120-92-3 cyclopentanone 
• 79-37-8 oxalyl dichloride 
• 1191-95-3 cyclobutanone 
• 65864-99-5 1-(diazomethyl)-3-methoxybenzene 
• 2398-37-0 3-methoxyphenyl bromide 
• 142144-65-8 1-(3-methoxyphenyl) cyclopentan-1-ol 
• 31600-88-1 m-methoxyphenyllithium 
• 36282-40-3 (3-methoxyphenyl)magnesium bromide 
• 36742-36-6 1-(3-methoxyphenyl)cyclopentene 

Downstream Products

• 61321-35-5 2-(3-Dimethylaminopropyl)-2-(3-methoxyphenyl)cyclopentanon 
• 342405-60-1 2-(3-Methoxyphenyl)-2-(2-dimethylaminoethyl)-cyclopentanon 
• 1026535-64-7 trifluoro-methanesulfonic acid 6-(3-methoxy-phenyl)-5,6-dihydro-4H-pyran-2-yl ester 
• 64417-34-1 5-(N-Carbethoxy-N-methylaminoethyl)-5-(3-methoxyphenyl)-cyclopent-2-enon 
• 64417-33-0 2-(N-Carbethoxy-N-methylaminoethyl)-2-(3-methoxyphenyl)-cyclopentanon 
• 64417-35-2 2-Brom-5-(N-Carbethoxy-N-methylaminoethyl)-5-(3-methoxyphenyl)-cyclopent-2-enon 
• 907214-18-0 [2-(3-methoxy-phenyl)-cyclopent-1-enyl]-acetic acid ethyl ester 
• 1253111-92-0 (2S,3S)-2-(3-methoxyphenyl)-2-(2-nitro-1-phenylethyl)cyclopentanone 
• 1270290-39-5 (+)-(S)-δ-(3-methoxyphenyl)-δ-valerolactone 
• 31517-43-8 2-(3-Methoxyphenyl)-cyclopentanon-oxim 

Relevant academic research and scientific papers

Diversity-Oriented Synthesis of Bioactive Azaspirocycles

A collection of novel azaspirocyclic β-arylethylamines was prepared in good yield and excellent diastereoselectivity by an expedient strategy that features condensation of a cyclic ketone with an amino allylsilane and a tandem aza-Sakurai cyclization to generate several different spirocyclic N-heterocycles. Subsequent elaboration of the spirocyclic scaffold was achieved via Pictet-Spengler cyclizations, Suzuki cross-coupling reactions, N-functionalizations, and olefin refunctionalization reactions to create a diverse library of compounds, several of which have nanomolar affinity for the sigma 1 receptor and transmembrane protein 97 (TMEM97).

Copper-catalyzed ring-opening C(sp3)-N coupling of cycloketone oxime esters: Access to 1°, 2° and 3° alkyl amines

A novel copper-catalyzed C(sp3)-N coupling of cycloketone oxime esters with nitrogen nucleophiles has been realized. All of the N-aryl/alkylanilines, anilines and benzophenone imine could be employed in this protocol to produce a variety of 1°, 2° and 3° alkyl amines in one or two steps. These resultant cyano-containing alkyl amines were proven to be versatile synthetic building blocks in a variety of chemical transformations.

Regio- and enantioselective Baeyer-Villiger oxidation: Kinetic resolution of racemic 2-substituted cyclopentanones

A kinetic resolution of racemic 2-substituted cyclopentanones via highly regio- and enantioselective Baeyer-Villiger oxidation has been successfully developed. The reaction could afford the normal 6-substituted δ-lactones in up to 98% ee and >19/1 regioselectivity. Meanwhile, the unreacted ketones were recovered in excellent ee values (up to 98%). It represents the best results of the kinetic resolution of racemic 2-substituted cyclopentanones via nonenzymic asymmetric BV oxidation.

Highly efficient and enantioselective α-arylation of cycloalkanones by scandium-catalyzed diazoalkane-carbonyl homologation

Functionalized α-tertiary and -quaternary 2-arylcycloalkanones are rapidly accessed by scandium(III) triflate-catalyzed diazo-alkane-carbonyl homologations. Recent developments have allowed for carbon insertion reactions to be performed with catalyst loadings as low as 0.5 mol% on scales up to 5 mmol. Pairing readily available bis- and tris(oxazoline) based ligands with scandium triflate allows access to arylated medium ring carbocycles with enantioselectivities up to 98:2 er and >98% yield. The formal C-C insertion of aryldiazo-methanes into unsubstituted cycloalkanones provides a single-step solution to the ongoing challenge of α-arylation. Georg Thieme Verlag Stuttgart · New York.

SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS

The present invention relates to novel tetralin ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.

4,5-diaryloxazole derivatives

Heterocyclic compounds of the formula: whereinR1 is carboxy or protected carboxy, R2 is aryl which may have suitable substituent(s), R3 is aryl which may have suitable substituent(s), A1 is lower alkylene, A2 is bond or lower alkylene and -Q- is etc., and pharmaceutically acceptable salts thereof which are useful as a medicament.

Synthesis and pharmacological activity of 6-aryl-2-azabicyclo[4.2.1]nonanes

A series of 6-phenyl-, 6-(m-methoxyphenyl)- and 6-(m-hydroxyphenyl)-2-azabicylo[4.2.1]nonanes was synthesized by a sequence involving alkylation of an appropriate 2-arylcyclopentanone with an aminoalkyl substituent. Subsequent ring closure at the other α